Patents Examined by Nina Ossanna
-
Patent number: 5189019Abstract: A protein having a molecular weight of about 6,000 daltons which is biologically active in the inhibition of Factor Xa during the blood coagulation cascade, a method for producing the protein, methods for inhibiting blood coagulation using the protein, and suitable pharmaceutical compositions.Type: GrantFiled: April 23, 1990Date of Patent: February 23, 1993Assignee: Merck & Co., Inc.Inventors: Linda O. Palladino, Melvin Silberklang, Jwu-Sheng Tung, Simon W. Law, George E. Mark
-
Patent number: 5187268Abstract: A substantially pure, synthetic protein possessing anti-complement property and a DNA sequence encoding said protein are described.Type: GrantFiled: July 1, 1992Date of Patent: February 16, 1993Assignee: United States of AmericaInventors: Girish Kotwal, Bernard Moss
-
Patent number: 5187153Abstract: Pharmaceutical compositions containing a 57 amino acid protease inhibitor and uses for those compositions are taught. The protease inhibitor is referred to as A4i which is associated with Alzheimer's disease. In addition to the A4i protease, other analogs are taught as are pharmaceutical compositions containing such analogs and their uses in treating a variety of abnormalities associated with Kunitz-type basic protease inhibitors. For example, it has been found that pharmaceutical compositions containing A4i protease and analogs thereof inhibit plasmin and tryptase, and also inhibit pancreatic trypsin, alpha-chymotrypsin, tissue kallikrein and serum kallikrein. In that certain diseases are associated with a general release of proteases such as trypsin, chymotrypsin and elastase into the circulatory system pharmaceutical compositions containing A4i and analogs thereof can be used in the management of such diseases.Type: GrantFiled: March 29, 1990Date of Patent: February 16, 1993Assignee: Scios Nova Inc.Inventors: Barbara Cordell, James W. Schilling, Nobuhiko Katunuma
-
Patent number: 5182260Abstract: The present invention relates to polypeptide inhibitors of platelet activation and derivatives thereof, purified from the venom of the North American Water Moccasin and to methods for their purification. This invention also relates to DNA sequences and recombinant DNA molecules which code for these polypeptide inhibitors of platelet activation. And this invention relates to recombinant DNA molecules which code for fusion proteins comprising both a polypeptide inhibitor of platelet activation and an anti-thrombin polypeptide. This invention also relates to pharmaceutically acceptable compositions and methods characterized by at least one of these natural or recombinant inhibitors of platelet activation, alone or in combination with anti-thrombin compounds. The compositions, combinations and methods of this invention are particularly useful in the treatment of thrombotic diseases.Type: GrantFiled: November 1, 1989Date of Patent: January 26, 1993Assignees: Biogen, Inc., Trustees of Boston UniversityInventors: John M. Maraganore, Joseph A. Jakubowski
-
Patent number: 5180667Abstract: DNA encoding novel eglin mutants that differ from the natural eglins B and C by the replacement of amino acids in the region of the active center (amino acid 45) by other amino acids are provided. The mutants, which are produced by recombinant genetic engineering, have valuable pharmacological properties.Type: GrantFiled: October 11, 1991Date of Patent: January 19, 1993Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AGInventors: Markus G. Grutter, Dirk Heinz, Manfred Liersch
-
Patent number: 5180810Abstract: A gene coding for Protein H, which is capable of binding specifically to human IgG of all subclasses, was isolated from Streptococcus sp. APl and expressed in host cells, E. coli to produce the Protein H.Type: GrantFiled: July 7, 1989Date of Patent: January 19, 1993Assignees: Sumitomo Chemical Co., Limited, HighTech Receptor ABInventors: Hideyuki Gomi, Tatsunobu Hozumi, Shizuo Hattori, Chiaki Tagawa, Fumitaka Kishimoto, Lars Bjorck
-
Patent number: 5179081Abstract: A polypeptide having an amino acid sequence as shown in FIG. 1 and its preparation method are disclosed. A DNA fragment capable of coding CPBII polypeptide (human placenta-derived coagulation inhibitor) is first obtained from the human placental cDNA library by using a CPBII-specific antibody as a probe. Then, microorganism cells are transformed by the use of a recombinant plasmid incorporated with the DNA fragment, allowing the resultant transformant to express the CPBII gene, to finally obtain a CPBII-like polypeptide. The polypeptide of this invention exhibits strong anticoagulation activities, and useful for an active component of anticoagulation medicines and preventin in vivo blood coagulation.Type: GrantFiled: May 1, 1991Date of Patent: January 12, 1993Assignee: Kowa Co., Ltd.Inventors: Akio Iwasaki, Makoto Suda, Yushi Saino
-
Patent number: 5179195Abstract: Genes and DNA transfer vectors for the expression of human preprorelaxin; sub-units thereof, including genes and transfer vectors for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.Type: GrantFiled: March 6, 1991Date of Patent: January 12, 1993Assignee: Howard Florey Institute of Experimental Physiology and MedicineInventors: Peter J. Hudson, Hugh D. Niall, Geoffrey W. Tregear
-
Patent number: 5165925Abstract: A vaccine for simultaneously immunizing large numbers of fish against infection by InfecThis invention was made with government support under the following grant numbers awarded by the U.S. Department of Commerce, National Oceanic and Atmospheric Administration, Science and Education Administration: NA81AA-D-00086 (1982-85, Recombinant DNA Technology in Aquaculture, Project No. R/FSD-9, Oregon State University); NA85AA-D-SG-095 (1985-87, Development of a Subunit Vaccine for IPNV, Project No. R/FSD-11, Oregon State University); and NA85AA-D-SG-095 (1987-89, Control of Virus Diseases in Fish, Project No. R/FSD-13, Oregon State University). The government has certain rights in this invention.Type: GrantFiled: May 2, 1989Date of Patent: November 24, 1992Assignee: State of Oregon Acting by and Through the State Board of Higher Education on behalf of Oregon State UniversityInventor: Jo-ann C. Leong
-
Patent number: 5162498Abstract: Synthetic yeast leader peptides are disclosed which aid in extracellular secretion of heterologous proteins made recombinantly in yeast.Type: GrantFiled: September 12, 1989Date of Patent: November 10, 1992Assignee: Novo Nordisk A/SInventor: Lars Christiansen
-
Patent number: 5157110Abstract: A substantially pure, synthetic protein possessing anti-complement property and a DNA sequence encoding said protein are described.Type: GrantFiled: August 20, 1988Date of Patent: October 20, 1992Assignee: The Government of the United States of AmericaInventors: Girish Kotwal, Bernard Moss
-
Patent number: 5149781Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences.Type: GrantFiled: June 20, 1988Date of Patent: September 22, 1992Assignee: Institut PasteurInventors: Hugues Blaudin de THE, Agnes Marchio, Pierre Tiollais, Anne Dejean
-
Patent number: 5145962Abstract: Genes and DNA transfer vector for the expression of human preprorelaxin; subunits thereof, including genes and transfer vectors for expression of human prorelaxin and the individual A, B and C peptide chains thereof; and equivalents of all such genes. Methods for synthesis of the peptides involving recombinant DNA techniques.Type: GrantFiled: April 8, 1991Date of Patent: September 8, 1992Assignee: Howard Florey Institute of Experimental Physiology and MedicineInventors: Peter J. Hudson, John Shine, Hugh D. Niall, Geoffrey W. Tregear
-
Patent number: 5144007Abstract: This invention provides a substantially purified thyroid hormone receptor, termed herbA-T, defined by its complete amino acid sequence deduced from its cDNA and the binding of thyroid hormone by the protein translated from the mRNA corresponding to the cDNA. The cDNA, the protein produced from it, and antibodies reactive therewith are also provided.Type: GrantFiled: October 24, 1990Date of Patent: September 1, 1992Assignee: La Jolla Cancer Research FoundationInventor: Magnus Pfahl
-
Patent number: 5130417Abstract: An Entamoeba histolytica specific cDNA clone which encodes an antigenic surface membrane protein possessing multiple tandem repeats and expression in E. coli is disclosed.Type: GrantFiled: April 30, 1990Date of Patent: July 14, 1992Assignee: Washington UniversityInventors: Samuel L. Stanley, Jr., Ellen Li
-
Patent number: 5122594Abstract: DNA sequences encoding modified varieties of human PSTI possessing excellent stability in terms of decreased susceptibility to decomposition by proteolytic enzymes such as trypsin, as compared with natural human PSTI, as well as the modified varieties of human PSTI obtained by the expression of the DNA sequences.Type: GrantFiled: July 12, 1989Date of Patent: June 16, 1992Assignee: Shionogi & Co., Ltd.Inventors: Nobuo Yoshida, Norihisa Kikuchi, Masaru Shin, Hiroshi Teraoka
-
Patent number: 5109113Abstract: Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.Type: GrantFiled: August 6, 1987Date of Patent: April 28, 1992Assignees: Genentech, Inc., New York UniversityInventors: Ingrid W. Caras, Michael A. Davitz, Victor Nussenzweig, David W. Martin, Jr.
-
Patent number: 5097026Abstract: Complementary DNA (cDNA) probes or fragments derived from these for human regulatory subunits of cAMP-dependent protein kinases. Human cDNA's for regulatory subunits (RI.alpha. and RII.beta.) of cAMP-dependent protein kinases have been identified and cloned.Type: GrantFiled: June 28, 1988Date of Patent: March 17, 1992Inventor: Tore Jahnsen
-
Patent number: 5093322Abstract: The invention relates to a new active substance--amblyommin--for anticoagulant therapy and to a process for the isolation thereof from hard ticks. The isolated protein having a thrombin-inhibitory action has a molecular weight of 20000 to 30000 dalton, an isoelectric point between 5.05 and 5.65 and the partial amino acid sequencesIle-Leu-Phe-Thr-Gln-Gly-Asn-X-Gly-Glu-Leu-Glu-Asn-X-Phe-Glu-,Lys-Ile-Leu-Phe-X-Gln-Gly- andAla-Ser-Tyr-Ile-Val-X-Ser-Glu-Ser-Ile-Gln-Ile-Leu-X-Leu-Ser-Glu-Gly-Ile-in which each radical X can be identical or different and each represents a naturally occurring amino acid.Type: GrantFiled: June 2, 1989Date of Patent: March 3, 1992Assignee: Hoechst AktiengesellschaftInventors: Werner Bonin, Paul Habermann, Dominique Tripier, Elisabet Wohner
-
Patent number: 5087613Abstract: The present invention relates to hirudin variants having a modified peptide structure, relative to a parent hirudin variant. The new hirudin variants of the present invention display improve biological properties relative to the parent variant.Type: GrantFiled: March 8, 1989Date of Patent: February 11, 1992Assignee: Transgene S.A.Inventors: Michael Courtney, Eric Degryse, Gerard Loison